DE602005011321D1 - Deamidiertes interferon-beta - Google Patents

Deamidiertes interferon-beta

Info

Publication number
DE602005011321D1
DE602005011321D1 DE602005011321T DE602005011321T DE602005011321D1 DE 602005011321 D1 DE602005011321 D1 DE 602005011321D1 DE 602005011321 T DE602005011321 T DE 602005011321T DE 602005011321 T DE602005011321 T DE 602005011321T DE 602005011321 D1 DE602005011321 D1 DE 602005011321D1
Authority
DE
Germany
Prior art keywords
beta
deamidated
interferon
deamided
interferon beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005011321T
Other languages
English (en)
Inventor
Kenji Furuya
Deborah Johnson-Jackson
Diana Tierra Ruscio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE602005011321D1 publication Critical patent/DE602005011321D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602005011321T 2004-11-10 2005-11-10 Deamidiertes interferon-beta Active DE602005011321D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
PCT/US2005/040758 WO2006053134A2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Publications (1)

Publication Number Publication Date
DE602005011321D1 true DE602005011321D1 (de) 2009-01-08

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011321T Active DE602005011321D1 (de) 2004-11-10 2005-11-10 Deamidiertes interferon-beta

Country Status (16)

Country Link
US (2) US7595040B2 (de)
EP (1) EP1809662B1 (de)
JP (1) JP4891250B2 (de)
KR (1) KR101330626B1 (de)
CN (1) CN101056890B (de)
AT (1) ATE415421T1 (de)
AU (1) AU2005304486B2 (de)
BR (1) BRPI0517697A (de)
CA (1) CA2587061C (de)
DE (1) DE602005011321D1 (de)
ES (1) ES2318575T3 (de)
MX (1) MX2007004990A (de)
PL (1) PL1809662T3 (de)
PT (1) PT1809662E (de)
RU (1) RU2404190C2 (de)
WO (1) WO2006053134A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2658715A1 (en) * 2006-08-08 2008-02-21 Novartis Ag Recombinant interferon-beta with enhanced biological activity
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
CN106132983B (zh) * 2014-04-04 2021-03-26 阿雷斯贸易股份有限公司 新型IFN-β蛋白类似物
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
AU776600B2 (en) * 1999-07-28 2004-09-16 Genentech Inc. Compositions and methods for the treatment of tumors
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
KR100541850B1 (ko) 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
WO2006053134A3 (en) 2006-08-31
JP2008519769A (ja) 2008-06-12
KR101330626B1 (ko) 2013-11-18
CN101056890B (zh) 2012-05-09
EP1809662B1 (de) 2008-11-26
US20060120998A1 (en) 2006-06-08
WO2006053134A2 (en) 2006-05-18
PL1809662T3 (pl) 2009-07-31
RU2404190C2 (ru) 2010-11-20
US7595040B2 (en) 2009-09-29
CA2587061A1 (en) 2006-05-18
US20090263355A1 (en) 2009-10-22
RU2007121515A (ru) 2008-12-20
KR20070084559A (ko) 2007-08-24
BRPI0517697A (pt) 2008-10-14
ES2318575T3 (es) 2009-05-01
CA2587061C (en) 2011-08-16
AU2005304486A1 (en) 2006-05-18
CN101056890A (zh) 2007-10-17
PT1809662E (pt) 2009-02-26
EP1809662A2 (de) 2007-07-25
ATE415421T1 (de) 2008-12-15
JP4891250B2 (ja) 2012-03-07
MX2007004990A (es) 2007-06-14
AU2005304486B2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
ATE415421T1 (de) Deamidiertes interferon-beta
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
BRPI0514790A (pt) muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
ATE388963T1 (de) Homogene herstellungen von il-29
NZ754961A (en) Growth differentiation factor 15 (gdf-15) constructs
BRPI0516455A (pt) fitase de citrobacter freundii e homólogos
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
EP1773867A4 (de) Proteinartige verbindungen und anwendungen davon
ATE400189T1 (de) Abgabe von mitteln zur krankheitskontrolle in aquakultur unter verwendung von bioaktive proteine enthaltender hefe
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
MX2021007434A (es) Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica.
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
Guo et al. Molecular cloning and characterization of a novel bovine IFN-ε
Ketscher et al. ISG15 uncut: Dissecting enzymatic and non-enzymatic functions of USP18 in vivo
Hauck et al. Effects of synthesized elastin peptides on human leukocytes.
ATE403726T1 (de) Cytokin-proteinfamilie
MX2009007248A (es) Peptidos bio-activos cortos para modulacion celular e inmunologica.
MX2009001348A (es) Interferon-beta recombinante con actividad biologica mejorada.
Andersen et al. Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition